March 16 (Reuters) - :Moderna Announces First Participants Dosed In Phase 2/3 Study Of Covid-19 Vaccine Candidate In Pediatric Population.
Moderna - Study Will Evaluate Safety, Tolerability & Effectiveness Of Two Doses Of Mrna-1273 In Pediatric Participants Given 28 Days Apart.
Moderna - Phase 2/3 Mrna-1273 Study Expected To Enroll 6,750 Healthy Pediatric Participants With Ages 6 Months To Less Than 12 Years In U.S. & Canada.Further Company Coverage: Mrna.O.
((Reuters.Briefs@Thomsonreuters.Com;)).
精彩评论